Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Nkarta, Inc. (NKTX)

2.8600 +0.0800 (+2.88%)
As of 9:43:14 AM EDT. Market Open.
Trade Nkarta on Coinbase
Chart Range Bar
Loading chart for NKTX
  • Previous Close 2.7800
  • Open 2.7800
  • Bid 2.0300 x 200
  • Ask 3.5500 x 200
  • Day's Range 2.7700 - 2.8600
  • 52 Week Range 1.6300 - 3.6500
  • Volume 23,407
  • Avg. Volume 759,448
  • Market Cap (intraday) 204.62M
  • Beta (5Y Monthly) 0.90
  • PE Ratio (TTM) --
  • EPS (TTM) -1.3500
  • Earnings Date (est.) Aug 12, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 11.33

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

www.nkartatx.com

108

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 6/26/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NKTX
54.59%
S&P 500 (^GSPC)
6.91%

1-Year Return

NKTX
65.32%
S&P 500 (^GSPC)
19.17%

3-Year Return

NKTX
36.87%
S&P 500 (^GSPC)
69.06%

5-Year Return

NKTX
90.28%
S&P 500 (^GSPC)
70.96%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -27.41M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-30M
-20M
-10M
0

Analyst Insights

View More

Analyst Price Targets

9.00
11.33 Average
2.8600 Current
16.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/13/2026
Analyst Needham
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 11 -> 11

Statistics

View More

Valuation Measures

Annual
As of 6/25/2026
  • Market Cap

    199.61M

  • Enterprise Value

    44.18M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.70

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -17.10%

  • Return on Equity (ttm)

    -30.07%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -99.93M

  • Diluted EPS (ttm)

    -1.3500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    230.43M

  • Total Debt/Equity (mrq)

    26.24%

  • Levered Free Cash Flow (ttm)

    -57.38M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.8600 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: